AVI BioPharma, Inc. (NASDAQ:AVII)
CAPS Rating:
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
Market-Beating Community Intelligence
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
just picked up a few shares monday for 3.05 a share on the basis the D.O.D. gave them a VERY SMALL chunk of change, I think just barely above $7mil to develope some homeland security vacines. The 52 wk high is more than double the current price. blah blah blah, it was an impulse buy.